SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine. Its orthobiologics products include demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to enhance bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company offers orthobiologics products in various forms, such as putties, pastes, strips, and resorbable mesh. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in minimally invasive, complex, deformity, and degenerative procedures. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPNE
Previous Symbol
CUSIPN/A
Phone760-727-8399
Debt
Debt-to-Equity Ratio0.08
Current Ratio2.91
Quick Ratio1.31
Price-To-Earnings
Trailing P/E Ratio-6.60
Forward P/E Ratio-8.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$131.81 million
Price / Sales2.40
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.87 per share
Price / Book2.17
Profitability
EPS (Most Recent Fiscal Year)($2.58)
Net Income$-32,110,000.00
Net Margins-22.60%
Return on Equity-30.81%
Return on Assets-23.53%
Miscellaneous
Employees327
Outstanding Shares18,530,000
Market Cap$318.58 million
OptionableOptionable
SeaSpine (NASDAQ:SPNE) Frequently Asked Questions
What is SeaSpine's stock symbol?
SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."
How were SeaSpine's earnings last quarter?
SeaSpine Holdings Corp (NASDAQ:SPNE) issued its quarterly earnings results on Tuesday, November, 6th. The medical equipment provider reported ($0.65) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.12. The medical equipment provider had revenue of $35.83 million for the quarter, compared to analysts' expectations of $35.56 million. SeaSpine had a negative return on equity of 30.81% and a negative net margin of 22.60%. View SeaSpine's Earnings History.
When is SeaSpine's next earnings date?
What guidance has SeaSpine issued on next quarter's earnings?
SeaSpine issued an update on its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $141-142 million, compared to the consensus revenue estimate of $141.16 million.
What price target have analysts set for SPNE?
5 analysts have issued twelve-month target prices for SeaSpine's stock. Their forecasts range from $17.00 to $23.00. On average, they anticipate SeaSpine's stock price to reach $20.20 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for SeaSpine.
What is the consensus analysts' recommendation for SeaSpine?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SeaSpine.
What are Wall Street analysts saying about SeaSpine stock?
Here are some recent quotes from research analysts about SeaSpine stock:
- 1. According to Zacks Investment Research, "SeaSpine Holdings Corporation is a medical technology company which focused on the design, development and commercialization of surgical solutions for the treatment of spinal disorders. The company also offers orthobiologics and spinal fusion hardware solutions. SeaSpine Holdings Corporation is headquartered in Vista, California. " (11/16/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $16 PT on shares of SPNE. SPNE reported solid 2Q results, with revenue of $36.4MM (+6.5%), beating FactSet consensus by $1.8MM and exceeding the company’s expectations of low-single-digit growth. The company continues to execute on its plan to drive market penetration from new products across both spinal implants and orthobiologics and from a more-engaged and increasingly exclusive distributor network. SPNE posted the highest overall and US revenue growth rates since the spin. US spinal implants (+11.5%) stood out as SPNE has now become a share taker in spine. US orthobiologics (+4.0%) was solid, driven by its DBM franchise." (7/30/2018)
Has SeaSpine been receiving favorable news coverage?
Media stories about SPNE stock have trended extremely positive on Wednesday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SeaSpine earned a daily sentiment score of 5.0 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of SeaSpine's key competitors?
Some companies that are related to SeaSpine include Luminex (LMNX), Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT) and Antares Pharma (ATRS).
Who are SeaSpine's key executives?
SeaSpine's management team includes the folowing people:
- Mr. Keith C. Valentine, Pres, CEO & Director (Age 50)
- Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 47)
- Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 46)
- Carrie Mendivil, Head of Investor Relations
- Mr. John J. Winge, VP of Sales (Age 51)
Who are SeaSpine's major shareholders?
SeaSpine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.03%), Dimensional Fund Advisors LP (3.35%), The Manufacturers Life Insurance Company (3.14%), Vanguard Group Inc. (2.95%), Russell Investments Group Ltd. (3.34%) and Renaissance Technologies LLC (2.13%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Bradley, Michael Fekete, Patrick L Keran and Stuart Essig. View Institutional Ownership Trends for SeaSpine.
Which major investors are selling SeaSpine stock?
SPNE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FNY Investment Advisers LLC, FNY Investment Advisers LLC, BlackRock Inc., Hodges Capital Management Inc., Bridgeway Capital Management Inc. and Falcon Point Capital LLC. Company insiders that have sold SeaSpine company stock in the last year include John B Henneman III, Keith Bradley and Stuart Essig. View Insider Buying and Selling for SeaSpine.
Which major investors are buying SeaSpine stock?
SPNE stock was bought by a variety of institutional investors in the last quarter, including The Manufacturers Life Insurance Company , EAM Investors LLC, Dimensional Fund Advisors LP, Vanguard Group Inc., Russell Investments Group Ltd., Wedge Capital Management L L P NC, Acadian Asset Management LLC and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought SeaSpine stock in the last two years include Michael Fekete and Stuart Essig. View Insider Buying and Selling for SeaSpine.
How do I buy shares of SeaSpine?
Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SeaSpine's stock price today?
One share of SPNE stock can currently be purchased for approximately $17.04.
How big of a company is SeaSpine?
SeaSpine has a market capitalization of $318.58 million and generates $131.81 million in revenue each year. The medical equipment provider earns $-32,110,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. SeaSpine employs 327 workers across the globe.
What is SeaSpine's official website?
How can I contact SeaSpine?
SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]
MarketBeat Community Rating for SeaSpine (NASDAQ SPNE)
MarketBeat's community ratings are surveys of what our community members think about SeaSpine and other stocks. Vote "Outperform" if you believe SPNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
